1. Home
  2. TNGX vs PLMIU Comparison

TNGX vs PLMIU Comparison

Compare TNGX & PLMIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • PLMIU
  • Stock Information
  • Founded
  • TNGX 2014
  • PLMIU N/A
  • Country
  • TNGX United States
  • PLMIU
  • Employees
  • TNGX N/A
  • PLMIU 4
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • PLMIU
  • Sector
  • TNGX Health Care
  • PLMIU
  • Exchange
  • TNGX Nasdaq
  • PLMIU NYSE
  • Market Cap
  • TNGX 990.5M
  • PLMIU N/A
  • IPO Year
  • TNGX N/A
  • PLMIU N/A
  • Fundamental
  • Price
  • TNGX $9.75
  • PLMIU $10.21
  • Analyst Decision
  • TNGX Strong Buy
  • PLMIU
  • Analyst Count
  • TNGX 8
  • PLMIU 0
  • Target Price
  • TNGX $14.86
  • PLMIU N/A
  • AVG Volume (30 Days)
  • TNGX 851.2K
  • PLMIU N/A
  • Earning Date
  • TNGX 08-05-2024
  • PLMIU N/A
  • Dividend Yield
  • TNGX N/A
  • PLMIU N/A
  • EPS Growth
  • TNGX N/A
  • PLMIU N/A
  • EPS
  • TNGX N/A
  • PLMIU N/A
  • Revenue
  • TNGX $37,232,000.00
  • PLMIU N/A
  • Revenue This Year
  • TNGX N/A
  • PLMIU N/A
  • Revenue Next Year
  • TNGX $2.40
  • PLMIU N/A
  • P/E Ratio
  • TNGX N/A
  • PLMIU N/A
  • Revenue Growth
  • TNGX 49.72
  • PLMIU N/A
  • 52 Week Low
  • TNGX $2.88
  • PLMIU N/A
  • 52 Week High
  • TNGX $13.03
  • PLMIU N/A
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 57.31
  • PLMIU 34.85
  • Support Level
  • TNGX $8.93
  • PLMIU $10.20
  • Resistance Level
  • TNGX $9.96
  • PLMIU $18.00
  • Average True Range (ATR)
  • TNGX 0.60
  • PLMIU 0.60
  • MACD
  • TNGX -0.01
  • PLMIU -0.10
  • Stochastic Oscillator
  • TNGX 82.57
  • PLMIU 0.13

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About PLMIU PLUM ACQUISITION CORP I UNIT 1 COM & 1/5 WT EXP(15/03/2026)

Plum Acquisition Corp I is a blank check company.

Share on Social Networks: